Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02272790 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02272790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02272790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Phase II Study of Adavosertib Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
January 30, 2015
Completion date
March 8, 2023
Enrollment
95 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian, fallopian tube, peritoneal cancer, p53 mutation